Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark M Awad

Showing results (61-70 of 210) with videos related to

Pageof 21
Sort By:
Journal for Immunotherapy of Cancer|October 6, 2020
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLCAlissa Keegan, Biagio Ricciuti, Padric Garden, et al.
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Clinical Lung Cancer|February 22, 2025
Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset ValidationAnurag Saraf, John He, Kee-Young Shin, et al.
Cancer Immunology Research|February 12, 2016
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung CancerMizuki Nishino, Emily S Chambers, Curtis R Chong, et al.
Nature Communications|June 14, 2024
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersTaek-Chin Cheong, Ahram Jang, Qi Wang, et al.
Cancer Immunology Research|March 2, 2017
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsGuillermo De Velasco, Youjin Je, Dominick Bossé, et al.
JCO Precision Oncology|September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsJessica K Lee, Russell Madison, Anthony Classon, et al.
HGG Advances|June 21, 2024
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancerXinan Wang, Kangcheng Hou, Biagio Ricciuti, et al.
Frontiers in Oncology|April 16, 2019
Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 TherapyMuhammad Mohsin Fareed, Luke R G Pike, Andrew Bang, et al.
Pageof 21

Showing results (61-70 of 210) with videos related to

Sort By:
Pageof 21
Journal for Immunotherapy of Cancer|October 6, 2020
Plasma IL-6 changes correlate to PD-1 inhibitor responses in NSCLCAlissa Keegan, Biagio Ricciuti, Padric Garden, et al.
International Journal of Cancer|March 7, 2020
Phase 1 study of epacadostat in combination with atezolizumab for patients with previously treated advanced nonsmall cell lung cancerMatthew D Hellmann, Scott Gettinger, Laura Q M Chow, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2018
Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune DisordersGiulia C Leonardi, Justin F Gainor, Mehmet Altan, et al.
Clinical Lung Cancer|February 22, 2025
Association of Sarcopenia With Toxicity and Survival in Patients With Lung Cancer, a Multi-Institutional Study With External Dataset ValidationAnurag Saraf, John He, Kee-Young Shin, et al.
Cancer Immunology Research|February 12, 2016
Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung CancerMizuki Nishino, Emily S Chambers, Curtis R Chong, et al.
Nature Communications|June 14, 2024
Mechanistic patterns and clinical implications of oncogenic tyrosine kinase fusions in human cancersTaek-Chin Cheong, Ahram Jang, Qi Wang, et al.
Cancer Immunology Research|March 2, 2017
Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsGuillermo De Velasco, Youjin Je, Dominick Bossé, et al.
JCO Precision Oncology|September 3, 2021
Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment PatternsJessica K Lee, Russell Madison, Anthony Classon, et al.
HGG Advances|June 21, 2024
Additional impact of genetic ancestry over race/ethnicity to prevalence of KRAS mutations and allele-specific subtypes in non-small cell lung cancerXinan Wang, Kangcheng Hou, Biagio Ricciuti, et al.
Frontiers in Oncology|April 16, 2019
Palliative Radiation Therapy for Vertebral Metastases and Metastatic Cord Compression in Patients Treated With Anti-PD-1 TherapyMuhammad Mohsin Fareed, Luke R G Pike, Andrew Bang, et al.
Pageof 21